We&Win Diversification Co., Ltd.

We&Win Diversification Co., Ltd.

TTPEX:4113
13.65
TWD
-0.70
(-4.88%)
-0.90EPS
3.51BMarket Cap
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
12.53
14.18
4.48
2.44
4.05
9.03
4.5
1.01
6.63
0.4
2.45
26.29
2.64
1.1
Basic EPS, GAAP
3.66
4.57
1.3
0.14
0.39
0.67
-0.66
-0.49
0.62
-0.66
-0.69
3.55
-0.43
-0.9
Free Cash Flow per Basic Share
-7.12
-5.38
-3.75
-2.82
-1.84
0.67
2.4
-8.71
0.65
-7.15
-4.6
10.15
-12.67
-4.97
Dividend per Share
0.78
1.59
0.71
0.77
0.12
0.11
0.3
- -
0.29
0.39
- -
- -
0.85
- -
Book Value per Share
13.65
16.74
16.97
16.33
16.6
17.18
16.22
15.73
16.06
15.01
14.33
19.58
18.46
18.09
Tangible Book Value per Share
13.65
16.74
16.97
16.33
16.6
17.18
16.22
15.73
16.06
15.01
14.33
19.58
18.46
18.09
Basic Weighted Avg Shares
156
180
208
217
217
217
217
217
217
217
211
217
231
231
Sales/Revenue/Turnover
1,949
2,547
931
530
880
1,962
978
220
1,439
87
518
5,715
610
255
Operating Margin (%)
30.34
35.02
24.41
16.6
14.22
11.07
12.23
-19.88
13.84
-76.65
-1.32
18.28
-0.42
-20.01
Depreciation Expense
1
1
2
1
1
1
4
4
7
7
7
6
6
6
Net Income, GAAP
569
821
270
29
85
145
-144
-106
134
-144
-146
771
-100
-208
Effective Tax Rate (%)
0.94
3.82
6.12
26.35
2.11
5.56
- -
- -
0.8
- -
- -
20.06
- -
- -
Profit Margin (%)
29.18
32.23
28.96
5.54
9.71
7.41
-14.7
-48.15
9.29
-166.65
-28.13
13.49
-16.39
-81.68
Working Capital
2,732
3,559
3,465
3,514
3,879
3,810
4,105
3,472
3,935
3,986
3,618
4,928
3,442
3,780
LT Debt
447
788
168
495
496
497
999
557
1,152
1,543
1,474
1,278
615
795
Total Equity
2,440
3,236
3,685
3,547
3,606
3,731
3,523
3,417
3,487
3,259
3,113
4,525
4,267
4,180
Return on Invested Capital (%)
17.03
15.78
3.22
0.95
1.67
2.64
- -
- -
1.91
- -
- -
6.93
- -
- -
Return on Capital (%)
17.06
16.02
5.09
0.88
1.73
2.5
- -
- -
1.95
- -
- -
7.01
- -
- -
Return on Common Equity (%)
28.22
28.92
7.79
0.81
2.39
3.96
-3.96
-3.05
3.87
-4.28
-4.57
20.18
-2.28
-4.9

Capital Structure

TWD

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
9,284
9,188
9,504
LT Borrowings
561
740
743
LT Finance Leases
54
53
52
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
231
231
231
Market Capitalization
5,732
3,929
3,513

Working Capital

TWD

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
14,402
14,744
15,404
Cash, Cash Equivalents & STI
420
457
695
Accounts Receivable, Net
- -
- -
10
Inventories
13,498
13,791
14,191
Total Current Liabilities
10,960
10,881
11,624
Payables & Accruals
- -
- -
- -
ST Debt
9,284
9,188
9,504
Deferred Revenue
- -
- -
- -

Growth Rates

TWD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
2.35%
6.14%
-5.69%
Free Cash Flow
-230.01%
-381%
-232.63%
Net Income, GAAP
-122.78%
-234.99%
-112.98%
Sales/Revenue/Turnover
189.11%
374.56%
-89.32%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

TWD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
1,243
2,287
877
1,308
5,715
2025
473
70
29
37
610
2026
22
166
- -
- -
- -

Quarterly Earnings Per Share

TWD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.51
2.17
0.64
0.29
3.55
2025
0.06
-0.06
-0.17
-0.27
-0.43
2026
-0.22
-0.24
- -
- -
- -

Quarterly Dividends Per Share

TWD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
0.85
2026
- -
- -
- -
- -
- -

Company Description

CEO
Yung Yi Su
Full Time Employees
31
Sector
Finance
Industry
Real estate development
Address
No. 185, Fuguo Road Kaohsiung City KH Taiwan 813
IPO Date
Dec 12, 2002
Business
We & Win Diversification Co., Ltd. is engaged in the development, leasing, and sale of various real estate properties throughout Taiwan, with a primary focus in Kaohsiung. The company's operations extend to include significant investments in public infrastructure projects, along with the planning and execution of new town and community development initiatives. Furthermore, it participates in the wholesale distribution of medical equipment and conducts international trade activities. Established in 1987, the firm was previously known as Oncoprobe Biotech Inc. before adopting its current name in 2009, and its main office is located in Kaohsiung City, Taiwan.